aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:46 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $74.1M (39009.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 13, 2025 | Mar 14, 2024 | Mar 9, 2023 | Mar 14, 2022 |
| Revenue | $190.0K | $235.0K | $353.0K | $10.4M | – |
| Operating expenses | $77.8M | $68.1M | $55.3M | $56.8M | $34.0M |
| Research and development | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M |
| Selling, general and administrative | $17.6M | $13.8M | $13.0M | $14.0M | $10.8M |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M |
| EPS, basic | $-0.80 | $-0.86 | $-0.94 | $-1.60 | – |
| EPS, diluted | $-0.80 | $-0.86 | $-0.94 | $-1.60 | – |
| Weighted shares, basic | 93.0M | 74.3M | 53.6M | 28.4M | – |
| Weighted shares, diluted | 93.0M | 74.3M | 53.6M | 28.4M | – |
| Margins and growth | |||||
| Operating margin | -40856.3% | -28899.6% | -15557.8% | -446.8% | – |
| Net margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | – |
| Revenue growth, year over year | −19.1% | −33.4% | −96.6% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 13, 2025 | Mar 14, 2024 | Mar 9, 2023 | Mar 14, 2022 |
| Cash and equivalents | $10.7M | $11.1M | $22.5M | $9.98M | $2.34M |
| Total current assets | $80.2M | $82.0M | $103.0M | $80.9M | $113.6M |
| Property, plant and equipment | $4.26M | $4.85M | $5.53M | $3.06M | $543.0K |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M |
| Accounts payable | $3.89M | $4.32M | $3.53M | $3.11M | $1.03M |
| Total current liabilities | $15.1M | $15.0M | $16.4M | $13.9M | $6.01M |
| Shareholders' equity | $67.3M | $69.8M | $90.5M | $71.3M | $109.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 13, 2025 | Mar 14, 2024 | Mar 9, 2023 | Mar 14, 2022 |
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M |
| Capital expenditures | $77.0K | $65.0K | $4.21M | $1.64M | $192.0K |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M |
| Depreciation and amortization | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K |
| Stock-based compensation | $5.00M | $2.99M | $2.60M | $2.15M | $1.61M |
| Investing cash flow | -$5.05M | $17.2M | -$20.1M | $47.2M | -$91.6M |
| Financing cash flow | $66.0M | $39.9M | $66.2M | $5.45M | $110.0M |
| Net change in cash | -$1.03M | -$12.0M | $12.9M | $10.8M | -$14.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2630.0% | 1271.9% | 736.5% | 20.7% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 2.55M | −97.4% | SEC |
| Jul 31, 2026 | 98.1M | +0.1% | SEC |
| May 11, 2026 | 98.1M | +10.2% | SEC |
| Mar 2, 2026 | 98.1M | +10.3% | SEC |
| Oct 31, 2025 | 98.0M | +16.7% | SEC |
| Aug 1, 2025 | 98.0M | +29.3% | SEC |
| May 2, 2025 | 89.0M | +29.0% | SEC |
| Mar 7, 2025 | 88.9M | +31.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.